医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ZELTIQ® Aesthetics to Showcase CoolCurve+ Applicator at IMCAS Asia Hong Kong 2012

2012年10月04日 AM09:11
このエントリーをはてなブックマークに追加


 

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced Henry H. Chan, MD, PhD, FRCP, will perform a live demonstration of CoolCurve+, the newest addition to the applicator platform for the CoolSculpting® System, at the International Master Course on Aging Skin (IMCAS) Asia in Hong Kong on October 5, 2012. Developed for enhanced fit and tissue draw, the anatomically curved shape of the CoolCurve+ applicator allows physicians to treat a multitude of body shapes.

WHAT:

    Session 22 – Lasers, Lights, Energy-Based Devices
Live CoolSculpting Demonstration with CoolCurve+ Applicator
 

WHEN:

Friday, October 5, 10:10-10:30 a.m.
 

WHERE:

International Master Course on Aging Skin (IMCAS) Asia
InterContinental Hong Kong Hotel
18 Salisbury Road, Kowloon, Hong Kong SAR
Room 3
 

WHO:

Henry H. Chan, MD, PhD, FRCP

 

For more information about CoolCurve+ and CoolSculpting, visit ZELTIQ Aesthetics at Booth B08. Exhibition hours are as follows: Friday, October 5, 8:30 a.m. to 6 p.m.; Saturday, October 6, 8:30 a.m. to 2 p.m.

About ZELTIQ Aesthetics, Inc.

ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

CONTACT

Neo Derm for ZELTIQ
Colin Leung
+852 9303 0338
colin.leung@neoderm.com.hk

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc